Introduction End-stage renal disease is associated with high health-care costs and low quality of life compared with chronic kidney disease. The renoprotective effectiveness of angiotensin-converting enzyme inhibitors (ACEi) is largely determined by the ACE insertion/deletion (I/D) polymorphism. We determined the cost-effectiveness of ACEi therapy in nondiabetic nephropathy for the ACE II/ID and for the ACE DD genotype separately. Furthermore, we considered a selective screen-and-treat strategy in which patients are prescribed alternative, more effective, therapy based on their ACE (I/D) polymorphism. Methods Time-dependent Markov models were constructed; cohorts of 1000 patients were followed for 10 years. Data were mainly gathered from th...
Approximately 20–40% of diabetic patients develop nephropathy which is the leading cause of ESRD in ...
Background. Autosomal dominant polycystic kidney disease (ADPKD) is a renal disease characterized by...
Abstract Background The Angiotensin Converting Enzyme (ACE) insertion/deletion (I/D) polymorphism ha...
Introduction End-stage renal disease is associated with high health-care costs and low quality of li...
Introduction End-stage renal disease is associated with high health-care costs and low quality of li...
OBJECTIVE: This study aimed to assess the potential cost-effectiveness of testing patients with neph...
Background: Treating non-diabetic proteinuric patients with advanced renal disease with an angiotens...
One reason for the inadequacy of current renoprotective therapy and the persistent poor renal progno...
Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in Europe and the USA. Angiotens...
ACE genotype and ACE induced renoprotection in chronic proteinuric nephropathies.BackgroundWhether a...
Objective: Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in Europe and the USA...
Losartan treatment reduced renal outcomes in proteinuric patients with type 2 diabetes in the Reduct...
We examined whether the ACE gene insertion/deletion (I/D) polymorphism modulates renal disease progr...
Type 2 diabetes is the main cause of end-stage renal disease in Europe and the United States. Angiot...
Renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion/deletion ...
Approximately 20–40% of diabetic patients develop nephropathy which is the leading cause of ESRD in ...
Background. Autosomal dominant polycystic kidney disease (ADPKD) is a renal disease characterized by...
Abstract Background The Angiotensin Converting Enzyme (ACE) insertion/deletion (I/D) polymorphism ha...
Introduction End-stage renal disease is associated with high health-care costs and low quality of li...
Introduction End-stage renal disease is associated with high health-care costs and low quality of li...
OBJECTIVE: This study aimed to assess the potential cost-effectiveness of testing patients with neph...
Background: Treating non-diabetic proteinuric patients with advanced renal disease with an angiotens...
One reason for the inadequacy of current renoprotective therapy and the persistent poor renal progno...
Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in Europe and the USA. Angiotens...
ACE genotype and ACE induced renoprotection in chronic proteinuric nephropathies.BackgroundWhether a...
Objective: Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in Europe and the USA...
Losartan treatment reduced renal outcomes in proteinuric patients with type 2 diabetes in the Reduct...
We examined whether the ACE gene insertion/deletion (I/D) polymorphism modulates renal disease progr...
Type 2 diabetes is the main cause of end-stage renal disease in Europe and the United States. Angiot...
Renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion/deletion ...
Approximately 20–40% of diabetic patients develop nephropathy which is the leading cause of ESRD in ...
Background. Autosomal dominant polycystic kidney disease (ADPKD) is a renal disease characterized by...
Abstract Background The Angiotensin Converting Enzyme (ACE) insertion/deletion (I/D) polymorphism ha...